{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT04863950",
            "orgStudyIdInfo": {
                "id": "CTMS# 20-0148"
            },
            "organization": {
                "fullName": "The University of Texas Health Science Center at San Antonio",
                "class": "OTHER"
            },
            "briefTitle": "Investigator-Initiated Study of Imipramine Hydrochloride and Lomustine in Recurrent Glioblastoma",
            "officialTitle": "A Phase II, Investigator-Initiated Study of Imipramine Hydrochloride and Lomustine in Recurrent Glioblastoma",
            "therapeuticArea": [
                "Other"
            ],
            "study": "investigator-initiated-study-of-imipramine-hydrochloride-and-lomustine-in-recurrent-glioblastoma"
        },
        "statusModule": {
            "statusVerifiedDate": "2023-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2022-05-25",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-09",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-09",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2021-04-23",
            "studyFirstSubmitQcDate": "2021-04-23",
            "studyFirstPostDateStruct": {
                "date": "2021-04-28",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2023-07-31",
            "lastUpdatePostDateStruct": {
                "date": "2023-08-03",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "PRINCIPAL_INVESTIGATOR",
                "investigatorFullName": "William Kelly",
                "investigatorTitle": "Clinical Investigator",
                "investigatorAffiliation": "The University of Texas Health Science Center at San Antonio"
            },
            "leadSponsor": {
                "name": "The University of Texas Health Science Center at San Antonio",
                "class": "OTHER"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false,
            "isUsExport": true
        },
        "descriptionModule": {
            "briefSummary": "This study is designed as a single center, prospective, open label, single-arm therapeutic trial with both surgical and non-surgical cohorts."
        },
        "conditionsModule": {
            "conditions": [
                "Glioblastoma"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SINGLE_GROUP",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 25,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Imipramine Hydrochloride/Lomustine",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Drug: Lomustine",
                        "Drug: Imipramine Hydrochloride"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Lomustine",
                    "description": "For surgical cohort patients, lomustine will be initiated (C1D1) within 6 weeks of surgery as soon as patient is deemed by the investigator (or designee) to be recovered enough for chemotherapy. Initiation of lomustine must be initiated within 6 weeks. If patient cannot be safely initiated on lomustine within this timeframe then they will be replaced.\n\nFor non-surgical cohort patients (the decision for surgery is made independent of study participation), lomustine will be initiated on C1D1.\n\nFor both cohorts, lomustine will be administered as 110 mg/m2 PO once every 6 weeks.",
                    "armGroupLabels": [
                        "Imipramine Hydrochloride/Lomustine"
                    ],
                    "otherNames": [
                        "Gleostine"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Imipramine Hydrochloride",
                    "description": "For the surgical cohort, imipramine hydrochloride will be initiated within a minimum of 16 days to a maximum of 3 weeks prior to surgery. Imipramine hydrochloride will be administered as 50mg PO (oral) QHS (at bedtime) for 4 days followed by a dose increase (taper-up) of 50mg/day every fourth day to attain a maximum dose of 200mg/day in 16 days.\n\nFor non-surgical cohort patients (the decision for surgery is made independent of study participation), imipramine hydrochloride will be initiated on Cycle 1 Day 1. Imipramine hydrochloride will be administered as 50mg PO (oral) QHS (at bedtime) for 4 days followed by a dose increase (taper-up) of 50mg/day every fourth day, if tolerated, to attain a maximum dose of 200mg/day in 16 days.",
                    "armGroupLabels": [
                        "Imipramine Hydrochloride/Lomustine"
                    ],
                    "otherNames": [
                        "Trofranil"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Progression Free Survival",
                    "timeFrame": "6 months"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* The subject is at least 18 years of age\n* The subject has the ability to understand the purposes and risks of the study and to have signed a written informed consent form approved by the investigator's IRB/Ethics Committee\n* The subject has histologically confirmed glioblastoma\n* The subject has progression following standard combined modality treatment with radiation and temozolomide chemotherapy\n* The subject has an ECOG (Eastern Cooperative Oncology Group) performance status \u2264 2\n* The subject has a life expectancy of at least 3 months\n* The subject has acceptable liver function:\n* Bilirubin \u2264 1.5 times upper limit of normal\n* AST (aspartate aminotransferase) (SGOT) and ALT (alanine transaminase 0 (SGPT) \u2264 3.0 times upper limit of normal (ULN)\n* The subject has acceptable renal function:\n* Serum creatinine \u2264ULN\n* The subject has acceptable hematologic status (without hematologic support):\n* ANC (absolute neutrophil count) \u22651500 cells/uL\n* Platelet count \u2265100,000/uL\n* Hemoglobin \u22659.0 g/dL\n* All women of childbearing potential (not surgically sterilized or at least 1 year post-menopausal) must have a negative serum pregnancy test. Additionally, male and female subjects must agree to use effective means of contraception (surgical sterilization or the use or barrier contraception with either a condom or diaphragm in conjunction with spermicidal gel or an IUD) with their partner from entry into the study through 6 months after the last dose.\n\nExclusion Criteria:\n\n* The subject is receiving warfarin (or other coumarin derivatives) and is unable to switch to low molecular weight heparin (LMWH) before the first dose of study drug.\n* The subject has evidence of acute intracranial or intratumoral hemorrhage either by MRI or computerized tomography (CT) scan. Subjects with resolving hemorrhage changes, punctate hemorrhage, or hemosiderin are eligible.\n* The subject is unable to undergo MRI scan (eg, has pacemaker).\n* The subject has received enzyme-inducing anti-epileptic agents within 14 days of study drug (eg, carbamazepine, phenytoin, phenobarbital, primidone).\n* The subject has not recovered to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v5.0 Grade \u2264 1 from AEs (except alopecia, anemia and lymphopenia) due to surgery, antineoplastic agents, investigational drugs, or other medications that were administered prior to study drug.\n* The subject has evidence of wound dehiscence.\n* The subject is pregnant or breast-feeding.\n* The subject has a history of cardiac disease, including arrhythmia, conduction abnormality, congenital prolonged QT syndrome, myocardial infarction, unstable angina pectoris or congestive heart failure.\n* A prolonged QTc rhythm noted during initial ECG \\>480 ms.\n* The subject has serious intercurrent illness, such as:\n* Hypertension (two or more blood pressure \\[BP\\] readings performed at screening of \\> 150 mmHg systolic or \\> 100 mmHg diastolic) despite optimal treatment\n\n  * Non-healing wound, ulcer, or bone fracture\n  * Untreated hypothyroidism\n  * Unhealed rectal or peri-rectal abscess\n  * Uncontrolled active infection\n  * Stroke, or transient ischemic attack within 6 months\n* The subject has received any of the following prior anticancer therapy:\n\n  * Non-standard radiation therapy such as brachytherapy, systemic radioisotope therapy (RIT), or intra-operative radiotherapy (IORT). Note: stereotactic radiosurgery (SRS) is allowed\n  * Non-bevacizumab systemic therapy (including investigational agents and small- molecule kinase inhibitors) or non-cytotoxic hormonal therapy (eg, tamoxifen) within 7 days or 5 half-lives, whichever is shorter, prior to first dose of study drug\n  * Biologic agents (antibodies, immune modulators, vaccines, cytokines) within 21 days prior to first dose of study drug\n  * Nitrosoureas or mitomycin C within 42 days, or metronomic/protracted low-dose chemotherapy within 14 days, or other cytotoxic chemotherapy within 28 days, prior to first dose of study drug\n  * Prior treatment with carmustine wafers\n* Any current psychosis, uncontrolled mood disorder (as assessed by investigator) or suicidal ideation. Additionally, current or history of bipolar disorder is excluded.\n* Patients currently using SSRI, SNRI, MAO inhibitors, tramadol or trazodone who are unwilling to undergo taper.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "stdAges": [
                "CHILD",
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Epp Goodwin",
                    "role": "CONTACT",
                    "phone": "210 450 5798",
                    "email": "goodwine@uthscsa.edu"
                },
                {
                    "name": "Maggie Tomasini",
                    "role": "CONTACT",
                    "phone": "210 450 5962",
                    "email": "tomasinim@uthscsa.edu"
                }
            ],
            "overallOfficials": [
                {
                    "name": "William Kelly, MD",
                    "affiliation": "The University of Texas Health Science Center - Mays Cancer Center",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Mays Cancer Center, UT Health San Antonio",
                    "status": "RECRUITING",
                    "city": "San Antonio",
                    "state": "Texas",
                    "zip": "78229",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Epp Goodwin",
                            "role": "CONTACT",
                            "phone": "210-450-1000"
                        },
                        {
                            "name": "William Kelly, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 29.42412,
                        "lon": -98.49363
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "UNDECIDED"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000005909",
                    "term": "Glioblastoma"
                }
            ],
            "ancestors": [
                {
                    "id": "D000001254",
                    "term": "Astrocytoma"
                },
                {
                    "id": "D000005910",
                    "term": "Glioma"
                },
                {
                    "id": "D000018302",
                    "term": "Neoplasms, Neuroepithelial"
                },
                {
                    "id": "D000017599",
                    "term": "Neuroectodermal Tumors"
                },
                {
                    "id": "D000009373",
                    "term": "Neoplasms, Germ Cell and Embryonal"
                },
                {
                    "id": "D000009370",
                    "term": "Neoplasms by Histologic Type"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000009375",
                    "term": "Neoplasms, Glandular and Epithelial"
                },
                {
                    "id": "D000009380",
                    "term": "Neoplasms, Nerve Tissue"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M14850",
                    "name": "Recurrence",
                    "relevance": "LOW"
                },
                {
                    "id": "M9019",
                    "name": "Glioblastoma",
                    "asFound": "Glioblastoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4561",
                    "name": "Astrocytoma",
                    "relevance": "LOW"
                },
                {
                    "id": "M9020",
                    "name": "Glioma",
                    "relevance": "LOW"
                },
                {
                    "id": "M20446",
                    "name": "Neoplasms, Neuroepithelial",
                    "relevance": "LOW"
                },
                {
                    "id": "M19845",
                    "name": "Neuroectodermal Tumors",
                    "relevance": "LOW"
                },
                {
                    "id": "M20388",
                    "name": "Neuroectodermal Tumors, Primitive",
                    "relevance": "LOW"
                },
                {
                    "id": "M12318",
                    "name": "Neoplasms, Germ Cell and Embryonal",
                    "relevance": "LOW"
                },
                {
                    "id": "M12315",
                    "name": "Neoplasms by Histologic Type",
                    "relevance": "LOW"
                },
                {
                    "id": "M12320",
                    "name": "Neoplasms, Glandular and Epithelial",
                    "relevance": "LOW"
                },
                {
                    "id": "M12325",
                    "name": "Neoplasms, Nerve Tissue",
                    "relevance": "LOW"
                },
                {
                    "id": "T2518",
                    "name": "Glioblastoma",
                    "asFound": "Glioblastoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "T2519",
                    "name": "Glioma",
                    "relevance": "LOW"
                },
                {
                    "id": "T4092",
                    "name": "Neuroepithelioma",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000008130",
                    "term": "Lomustine"
                },
                {
                    "id": "D000007099",
                    "term": "Imipramine"
                }
            ],
            "ancestors": [
                {
                    "id": "D000018906",
                    "term": "Antineoplastic Agents, Alkylating"
                },
                {
                    "id": "D000000477",
                    "term": "Alkylating Agents"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                },
                {
                    "id": "D000000929",
                    "term": "Antidepressive Agents, Tricyclic"
                },
                {
                    "id": "D000000928",
                    "term": "Antidepressive Agents"
                },
                {
                    "id": "D000011619",
                    "term": "Psychotropic Drugs"
                },
                {
                    "id": "D000018759",
                    "term": "Adrenergic Uptake Inhibitors"
                },
                {
                    "id": "D000014179",
                    "term": "Neurotransmitter Uptake Inhibitors"
                },
                {
                    "id": "D000049990",
                    "term": "Membrane Transport Modulators"
                },
                {
                    "id": "D000018663",
                    "term": "Adrenergic Agents"
                },
                {
                    "id": "D000018377",
                    "term": "Neurotransmitter Agents"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M10147",
                    "name": "Imipramine",
                    "asFound": "Epicondylitis",
                    "relevance": "HIGH"
                },
                {
                    "id": "M11130",
                    "name": "Lomustine",
                    "asFound": "Biphasic",
                    "relevance": "HIGH"
                },
                {
                    "id": "M20942",
                    "name": "Antineoplastic Agents, Alkylating",
                    "relevance": "LOW"
                },
                {
                    "id": "M3820",
                    "name": "Alkylating Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M4247",
                    "name": "Antidepressive Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M4248",
                    "name": "Antidepressive Agents, Tricyclic",
                    "relevance": "LOW"
                },
                {
                    "id": "M14474",
                    "name": "Psychotropic Drugs",
                    "relevance": "LOW"
                },
                {
                    "id": "M20746",
                    "name": "Adrenergic Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M20504",
                    "name": "Neurotransmitter Agents",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "PsychDr",
                    "name": "Psychotropic Drugs"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                }
            ]
        }
    },
    "hasResults": false
}